



INVESTOR PRESENTATION

January 2020

SAFE HARBOR STATEMENT

This presentation contains "forward-looking statements" relating to future events, and we may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting Evogene Ltd. or its subsidiaries (collectively, "Evogene" or "we"), that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Such forward-looking statements may be identified by the use of such words as "believe," "expect," "anticipate," "should," "planned," "estimated," "intend" and "potential" or words of similar meaning. For these statements, Evogene claims the protection of the safe harbor for forward-looking statements contained in the PSLRA.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond Evogene's control, including, without limitation, those described in greater detail in our Periodical and Annual Reports, including our Registration Statement on Form F-1, Annual Report on Form 20-F and in other information we file and furnish with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including under the heading "Risk Factors."

All written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the previous statements. Except for any obligations to disclose information as required by applicable securities laws, Evogene disclaims any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or any other entity, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Evogene.

AGENDA

What we do

Evolution of
Evogene

Technological
approach

Target
markets

Corporate
structure &
activities

Summary

WHAT WE DO

Evogene is a leading company in leveraging computational biology to design novel products for life-science-based industries including:
human health, agriculture and industrial applications



Evolution

Established




Evogene positioned as a world leading gene-trait company

Plant gene traits Era


IPO NASDAQ

Computational Predictive Biology (CPB)




Computational Predictive Biology (CPB) platform established - expanding to genomics, chemistry and microbes

Computational Era




Internal divisions are formed to establish a proof of concept to targeted fields

Internal Divisions Era




Forming product focused companies in targeted fields



Tech-Hub & Subsidiary Era

THE CHALLENGE IN PRODUCT DEVELOPMENT

COMMON PRACTICE



Low probability of success


Long time to market

High development costs

Limited 'next generation' products in pipelines

EVOGENE'S SOLUTION


CANDIDATES WITH THE HIGHEST PROBABILITY OF SUCCESS



EVOGENE'S SOLUTION

CANDIDATES WITH THE HIGHEST PROBABILITY OF SUCCESS

The *CPB* Platform



Increasing
probability of
success



Reducing time
to market



Reducing
budget

B. Continuous support of the *CPB* in product optimization and development stages till commercialization

A. Computational prediction system for candidates addressing the majority of product criteria at Stage Zero

✓
Successful
Product
Launch


CPB PLATFORM – WHY NOW?

HARNESSING THE POWER OF THE COMPUTATIONAL REVOLUTION

Evogene's *CPB* platform leveraging the revolutions in **Big Data** and **Artificial Intelligence** together with a deep understanding of biology, to successfully address multiple product attributes at the beginning of the discovery process, rather than one at a time during the development phase



FIELDS OF DEVELOPMENT




TARGET MARKETS & FIELDS OF ACTIVITY




EVOGENE'S BUSINESS MODEL EXAMPLE


LAVIE BIO – FROM AN IDEA TO PRODUCTS



FROM A DIVISION TO A SUBSIDIARY



COMPANY STRUCTURE






Press Release • 8/7/2019

Corteva Agriscience to Invest in Evogene's Agriculture Biologicals Subsidiary, Lavie Bio

Investment Includes Equity and Corteva's Shares in Taxon Biosciences for Shares in Lavie Bio

Wilmington, Del., USA and Rehovot, Israel – Aug. 7, 2019 – Corteva, Inc. (NYSE: CTVA), a leading pure-play agriculture company, and Evogene Ltd. (NASDAQ, TASE: EVGN), a leading biotechnology company developing novel products for life science markets, announced today that Corteva will make an investment in Evogene's agriculture biologicals subsidiary, Lavie Bio (Lavie). The transaction includes the exchange of all shares of Corteva's wholly owned subsidiary Taxon Biosciences along with an equity investment by Corteva in Lavie. As consideration for the Taxon Biosciences shares and equity investment, Corteva will be issued approximately 30 percent of Lavie's equity while Evogene will hold approximately 70 percent of Lavie's equity.

COMPANY STRUCTURE






Canonix Announces Initiation of Cultivation and Breeding of Cannabis Varieties with Unique Genomic Profiles for the Development of Medical Cannabis Products

This announcement follows successfully importing a collection of widely genetically diverse cannabis lines, establishing specialized R&D facilities, and receiving regulatory approval from the Israeli Medical Cannabis Agency (IMCA)

Rehovot, Israel – November 6, 2019 – Canonix, a wholly owned subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN) focused on the development of medical cannabis products, announces today the initiation of its cultivation and breeding program of cannabis varieties with unique genomic profiles for the development of medical cannabis products. The initiation of cannabis cultivation follows: (1) successfully importing widely genetically diverse cannabis lines originating from different territories, (2) establishment of cannabis dedicated R&D facilities, including greenhouses, a molecular lab and tissue culture rooms and (3) receipt of the required regulatory approvals from the Israeli Medical Cannabis Agency (IMCA).

Canonix achieved an important milestone with the import of a genetically diverse seed collection of cannabis lines originating from different territories. These seeds were specifically selected to be the foundation of Canonix's advanced breeding program and product pipeline consisting of *MetaYield* – medical cannabis products with a stable increase of total plant active compounds, and *Precise* product line – medical cannabis with a stable increase of specific plant active compounds.

COMPANY STRUCTURE






Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program

The scale-up and GMP batch production is to support the preparation towards the anticipated first in man proof of concept clinical trials

Rehovot, Israel – January 13, 2020 – Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ, TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 & BMC127 for its Immuno-Oncology program. This agreement will accelerate the Company's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies.

Biose Industrie is a drug-GMP certified manufacturer of bacteria-based APIs and clinical and commercial products. Biomica engaged with Biose for the scale-up development and GMP production of a clinical batch of its drug candidates.

MILESTONE ROADMAP



SUMMARY

WHAT WE DO

We leverage computational biology to design novel products for life-science-based industries including human health, agriculture, and industrial applications.

OUR TECHNOLOGY – THE CPB PLATFORM

Utilizing artificial intelligence and other algorithms on unique biological BIG DATA with deep understanding of life-sciences, focusing on product candidates addressing the majority of product criteria at '[Stage Zero](#)'.

CPB CAPABILITIES FOR PREDICTION OF INNOVATION

- Genetic elements – controlling desired biological processes
- Small molecules – active ingredients for chemical based products
- Microbes – active ingredients for microbial based products

TARGET MARKETS AND CURRENT ACTIVITIES

- Agriculture - Ag-Chemicals, Seed Traits, Ag-Biologicals
- Human Health – Human Microbiome, Drug Discovery, Medical Cannabis
- Industrial Applications – Castor oil

MAIN COLLABORATIONS WITH WORLD-LEADING COMPANIES



CORPORATE STRUCTURE

Evogene and the CPB platform at the heart of a group of subsidiaries, each focused in different life-science based markets, with exclusive access to the CPB platform for their field of activity, providing their main competitive advantage for their product development pipeline.

FINANCIAL FUNDAMENTALS

- Cash position - \$ 52.1 M (Sep. 30, 2019), no debt
- Listed on TASE (2007) and NASDAQ (2013)



THANK YOU

Annex I: Financial Fundamentals

KEY FINANCIALS – BALANCE SHEET

Thousand US \$	30.09.2019	31.12.2018
Current Assets	53,828	55,488
Long-Term Assets	22,615*	3,206
Total Assets	76,443	58,694
Current Liabilities	4,729	5,431
Long-Term Liabilities	5,580	2,957
Equity attributable to equity holders of the Company	56,090	50,053
Non-controlling interest	10,044	253
Total Liabilities & Shareholders Equity	76,443	58,694

Key Points:

- Cash position: ~52 million USD as of 30.09.2019
- No debt
- Estimated net cash usage for 2019: \$16-\$18 million
- Listed on TASE (2007) and NASDAQ (2013)

*17,255 thousand dollars attributed to intangible assets (net) following Corteva's investment in Lavie Bio